Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma

Anamika Singh, Ariel Erijman, Ashish Noronha, Hemant Kumar, Yoav Peleg, Yosef Yarden, Julia M. Shifman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Within the superfamily of small GTPases, Ras appears to be the master regulator of such processes as cell cycle progression, cell division, and apoptosis. Several oncogenic Ras mutations at amino acid positions 12, 13, and 61 have been identified that lose their ability to hydrolyze GTP, giving rise to constitutive signaling and eventually development of cancer. While disruption of the Ras/effector interface is an attractive strategy for drug design to prevent this constitutive activity, inhibition of this interaction using small molecules is impractical due to the absence of a cavity to which such molecules could bind. However, proteins and especially natural Ras effectors that bind to the Ras/ effector interface with high affinity could disrupt Ras/effector interactions and abolish procancer pathways initiated by Ras oncogene. Using a combination of computational design and in vitro evolution, we engineered high-affinity Ras-binding proteins starting from a natural Ras effector, RASSF5 (NORE1A), which is encoded by a tumor suppressor gene. Unlike previously reported Ras oncogene inhibitors, the proteins we designed not only inhibit Ras-regulated procancer pathways, but also stimulate anticancer pathways initiated by RASSF5. We show that upon introduction into A549 lung carcinoma cells, the engineered RASSF5 mutants decreased cell viability and mobility to a significantly greater extent than WT RASSF5. In addition, these mutant proteins induce cellular senescence by increasing acetylation and decreasing phosphorylation of p53. In conclusion, engineered RASSF5 variants provide an attractive therapeutic strategy able to oppose cancer development by means of inhibiting of procancer pathways and stimulating anticancer processes.

Original languageAmerican English
Article number101353
JournalJournal of Biological Chemistry
Issue number6
StatePublished - 1 Dec 2021

Bibliographical note

Funding Information:
Funding and additional information—J. S. M. is supported by the Israel Science Foundation (ISF) grant 1873/15, Israel Cancer Research Fund (ICRF), and Binational US-Israel Science Foundation (BSF). Y. Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair in Molecular Cell Biology. His lab been supported by the ICRF, the ISF, the European Research Council (ERC; Oncombine Project), and the Dr Miriam and Sheldon G. Adelson Medical Research Foundation.

Publisher Copyright:
© 2021 American Society for Biochemistry and Molecular Biology Inc.. All rights reserved.


Dive into the research topics of 'Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this